

Clinical trials of angiogenesis inhibitors for lung cancer (metastatic) in all type of patients

TrialResults-center www.trialresultscenter.org

1 anti angiogenesis antibody

Trial	Treatments	Patients	Trials design and methods
bevacizumab vs			
65279;Reck , 2010 n=NA	GP+bev versus GP	-	
ramucirumab + docetaxel vs docetaxel alone			
REVEL , 2014 [NCT01168973] n=NA follow-up:	-	patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen	double-blind USA
bevacizumab + erlotinib vs erlotinib alone			
Herbst , 2011 n=NA	erl+bev versus erl	-	
bevacizumab vs platinum based CT			
Sandler , 2006 n=NA	PCp +bev versus PCp	-	
Johnson , 2004 n=NA	PCp +bev versus PCp	-	
Nishio , 2009 n=NA	PCp +bev versus PCp	-	
Herbst , 2007 n=NA	D/M +bev versus D/M	-	

References

65279;Reck, 2010:

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol* 2009;27:1227-34 [19188680] [10.1200/JCO.2007.14.5466](https://doi.org/10.1200/JCO.2007.14.5466)

REVEL, 2014:

Garon EB, Ciuleanu TE, Arrieta O, Prabhaskar K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of

stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet* 2014 Aug 23;384:665-73 [24933332] [10.1016/S0140-6736\(14\)60845-X](https://doi.org/10.1016/S0140-6736(14)60845-X)

Herbst, 2011:

Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. *Lancet* 2011;377:1846-54 [21621716] [10.1016/S0140-6736\(11\)60545-X](https://doi.org/10.1016/S0140-6736(11)60545-X)

Sandler, 2006:

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542-50 [17167137] [10.1056/NEJMoa061884](https://doi.org/10.1056/NEJMoa061884)

Johnson, 2004:

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004;22:2184-91 [15169807] [10.1200/JCO.2004.11.022](https://doi.org/10.1200/JCO.2004.11.022)

Nishio, 2009:

Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, et al. Randomized, openlabel, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naïve Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. available from: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8036> Accessed 2012 May 26

Herbst, 2007:

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. *J Clin Oncol* 2007;25:4743-50 [17909199] [10.1200/JCO.2007.12.3026](https://doi.org/10.1200/JCO.2007.12.3026)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.